comparemela.com

Latest Breaking News On - Jorge dimartino - Page 1 : comparemela.com

Pfizer's migraine market chief joins Apnimed—Chutes & Ladders

Pfizer's migraine market chief joins Apnimed—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

San-diego
California
United-states
France
Ireland
Connecticut
French
Paul-willems
Madam-townsend
Samuel-collins
Mary-lynne-hedley
Kirk-shepard

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Company eliminates three executive officer roles and appoints new Executive Leadership teamSAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 Kronos Bio, Inc. , a company dedicated to.

Cambridge
Cambridgeshire
United-kingdom
Charles-lin
Sarah-connors
Allison-frisbee
Norbert-bischofberger
Christopher-dinsmore
Elizabeth-olek
Rocio-martin-hoyos
Jorge-dimartino
Barbara-kosacz

Kronos Bio Inc. (KRON) Implements New Leadership Structure to Drive Pipeline Advancement

Kronos Bio Inc. (KRON) Implements New Leadership Structure to Drive Pipeline Advancement
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Kronos-bio
Elizabeth-olek
Charles-lin
Allison-frisbee
Christopher-dinsmore
Rocio-martin-hoyos
Norbert-bischofberger
Barbara-kosacz
Jorge-dimartino
Clinical-development
Nasdaq
Kronos-bio-inc

Kronos discontinues mid-stage AML trial after poor response

Kronos discontinues mid-stage AML trial after poor response
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Daiichi-sankyo
Roche-genentech
Kronos-bio
Jorge-dimartino
Norbert-bischofberger
Genentech

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New.

Cambridge
Cambridgeshire
United-kingdom
Norbert-bischofberger
Sarah-connors
Jorge-dimartino
Kronos-bio
Christopher-dinsmore
Kronos-bio-inc
Corporate-affairs
Business-development
Exchange-commission

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.